Illumina (NASDAQ: ILMN) reported Q3 EPS of $1.52, $0.26 better than the analyst estimate of $1.26. Revenue for the quarter came in at $853 million versus the consensus estimate of $828.59 million.

“Illumina’s strong performance in the third quarter of 2018 reflected growth across our sequencing and arrays portfolios,” said Francis deSouza, President and CEO. “Sequencing system revenue of $138 million was the strongest since 2015, reflecting strong demand within our sequencing family from the NovaSeq, the most powerful and flexible sequencer ever, to the iSeq, our most accessible and easiest-to-use sequencer.”

• Revenue of $853 million, a 20% increase compared to $714 million in the third quarter of 2017
• GAAP net income attributable to Illumina stockholders for the quarter of $199 million, or $1.33 per diluted share, compared to $163 million, or $1.11 per diluted share, for the third quarter of 2017
• Non-GAAP net income attributable to Illumina stockholders for the quarter of $227 million, or $1.52 per diluted share, compared to $163 million, or $1.11 per diluted share, for the third quarter of 2017 (see the table entitled “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” for a reconciliation of these GAAP and non-GAAP financial measures)
• Cash flow from operations of $292 million compared to $235 million in the third quarter of 2017
• Free cash flow (cash flow from operations less capital expenditures) of $228 million for the quarter, compared to $153 million in the third quarter of 2017

GUIDANCE:

Illumina sees FY2018 EPS of $5.70-$5.75, versus the consensus of $5.45.

For earnings history and earnings-related data on Illumina (ILMN) click here.